Delay Means New EU Clinical Trial Rules May Not Be Transferred To UK
Executive Summary
With the implementation of the EU Clinical Trials Regulation now postponed to the second half of 2019, it is unlikely that its provisions will be taken over into UK legislation as part of the Brexit “Repeal Bill” that will convert all EU laws and regulations into domestic UK law.
You may also be interested in...
EU Issues GMP Guide For Investigational Drugs Under Clinical Trials Regulation
A new EU guideline explains how manufacturers and importers of investigational medicinal products can comply with the provisions of a 2017 delegated regulation specifying good manufacturing practice requirements and inspection procedures for such products.
US Pharma Firms Warn ‘Hard’ Brexit Will Impact UK Investments; Clinical Trials A Casualty Of Uncertainty
A group of US pharmaceutical majors have said that their investments in the UK could be at risk if the UK leaves the EU without a Brexit deal, and that the UK could become a “secondary market” in terms of new drug launches. Meanwhile a major UK research institute says that the uncertainty is already causing drug sponsors to think twice about running clinical trials in the UK. A slowdown in pharma market growth is also foreseen.
Brexit Hits Life Science Investment Decisions As UK Risks Exclusion From Key EU Projects
The chief executives of the APBI and the BIA have told the House of Lords’ Science and Technology Committee that Brexit uncertainty is having an impact on life science investment decisions and that the UK may not be able to benefit from key EU legislative initiatives that it helped to create.